(Total Views: 656)
Posted On: 09/02/2025 6:31:08 PM
Post# of 158140
Nothing exciting but at least we get a mention....
Key Takeaways from the COVID-19 Pipeline Report
On 27 August 2025, CytoDyn Inc. announced the initiation of a Phase 2b/3 study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection. In this trial, patients will be randomized to receive either weekly doses of 700 mg leronlimab (PRO 140) or a placebo. Both leronlimab (PRO 140) and the placebo will be administered via subcutaneous injection.
https://www.barchart.com/story/news/34551923/...-companies
(5)
(0)
